Gilead Buys Out Rights To Cancer Therapy From Jounce For $67 Million

Gilead Buys Out Rights To Cancer Therapy From Jounce For $67 Million

(Reuters) – Gilead Sciences will buy all the remaining rights for an experimental cancer therapy, GS-1811, from Jounce Therapeutics for $67 million, the drugmaker said on Tuesday. The amended licensing deal will bolster Jounce’s cash resources in a challenging market for biotech companies. Shares of Jounce more than doubled to $1.68, while Gilead’s shares fell…

Read More
Japan Asks Its Insurers To Retain Marine War Cover For LNG Shippers In Russian Waters

Japan Asks Its Insurers To Retain Marine War Cover For LNG Shippers In Russian Waters

TOKYO (Reuters) – The Japanese government has asked insurers to take on additional risks to continue providing marine war insurance for liquefied natural gas (LNG) shippers in Russian waters, a senior official at the industry ministry said. The Financial Services Agency and Agency for Natural Resources and Energy made the rare request in a joint…

Read More
U.S. Probes How $370 Million Vanished In Hack After FTX Bankruptcy - Bloomberg News

U.S. Probes How $370 Million Vanished In Hack After FTX Bankruptcy – Bloomberg News

(Reuters) – Federal prosecutors are investigating an alleged cybercrime that drained more than $370 million from crypto exchange FTX hours after it filed for bankruptcy, Bloomberg News reported on Tuesday citing a person familiar with the case. The criminal probe into the stolen assets, launched by the Department of Justice is separate from fraud case…

Read More